FDA approves Lundbeck's Vyepti, the first CGRP inhibitor for migraine delivered IV

With little difference in efficacy or price, the CGRP competition will boil down to delivery, frequency and access

FDA's approval of Vyepti eptinezumab-jjmr from Lundbeck is the first for an IV-delivered CGRP inhibitor for migraine prevention, but the therapy will face competition from established subcutaneous drugs in its class.

Already on the

Read the full 337 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE